Accessibility StatementSkip Navigation - The collaboration will leverage General Proximity's OmniTACÂ platform to identify and advance next generation induced proximity agents for high value oncology targets. - Induced proximity medicines, powered by the OmniTACÂ platform, enable precise modulation of disease- driving and traditionally undruggable proteins. -Â General Proximity will identify novel effector-target pairs that can be exploited through induced proximity medicines. SAN FRANCISCO, Nov. 12, 2025 / ...